Title:

Real-world evidence of clinical outcomes of the use of the adalimumab biosimilar SB5 in rheumatic and digestive IMIDs: 12-month data from the PERFUSE study

Authors:

- Bruno Fautrel,
- Yoram Bouhnik,
- Carine Salliot,
- Franck Carbonnel,
- Mathurin Fumery,
- Christophe Bernardeau,
- Yves Maugars,
- Mathurin Flamant
- Fabienne Coury,
- * Ben Braithwaite,
- Janet Addison,
- On behalf of the PERFUSE investigators.

* Corresponding Author:

Ben Braithwaite, Sanoïa e-Health Services, Gémenos, France, 0000-0002-7378-1034

email address: bbraithwaite@sanoia.com

Supplementary Table S2: SNDS pairing statistics.

Supplementary Table S2 - A: Description of SNDS data

	Rheumatology				Gastroenterology			
	AS (N=313)	PSA (N=78)	RA (N=116)	Rheumatology (N=507)	CD (N=316)	UC (N=88)	Gastroenterology (N=404)	Total (N=911)
Information available in SNDS dataset								
No	221 (70.6%)	60 (76.9%)	87 (75.0%)	368 (72.6%)	203 (64.2%)	66 (75.0%)	269 (66.6%)	637 (69.9%)
Yes	92 (29.4%)	18 (23.1%)	29 (25.0%)	139 (27.4%)	113 (35.8%)	22 (25.0%)	135 (33.4%)	274 (30.1%)
Missing data	0	0	0	0	0	0	0	0
Time between last perfusion recorded in Imraldi database and SNDS information (in days)								
n	92	18	29	139	113	22	135	274
Mean (SD)	211.6 (241.7)	236.4 (257.8)	260.7 (252.3)	225.1 (245.0)	200.4 (232.8)	188.2 (220.7)	198.4 (230.1)	211.9 (237.7)
Median	187.5	223.5	271.0	211.0	201.0	193.5	201.0	203.5
Q1 - Q3	25.0 - 384.5	52.0 - 443.0	25.0 - 395.0	25.0 - 391.0	47.0 - 337.0	6.0 - 364.0	25.0 - 340.0	25.0 - 363.0
Range	-392.0 - 784.0	-280.0 - 633.0	-102.0 - 664.0	-392.0 - 784.0	-418.0 - 908.0	-258.0 - 567.0	-418.0 - 908.0	-418.0 - 908.0
Missing data	221	60	87	368	203	66	269	637
SNDS information after or before last perfusion recorded in Imraldi database								
After	74 (80.4%)	16 (88.9%)	22 (75.9%)	112 (80.6%)	90 (79.6%)	19 (86.4%)	109 (80.7%)	221 (80.7%)
Before	18 (19.6%)	2 (11.1%)	7 (24.1%)	27 (19.4%)	23 (20.4%)	3 (13.6%)	26 (19.3%)	53 (19.3%)
Missing data	221	60	87	368	203	66	269	637
Exposure before consideration of SNDS data for patients without confirmed SB5 discontinuation and with available SNDS data								
Less than 12 months	23 (29.9%)	3 (18.8%)	7 (28.0%)	33 (28.0%)	30 (29.4%)	5 (35.7%)	35 (30.2%)	68 (29.1%)
More than 12 months	54 (70.1%)	13 (81.3%)	18 (72.0%)	85 (72.0%)	72 (70.6%)	9 (64.3%)	81 (69.8%)	166 (70.9%)
Missing data	0	0	0	0	0	0	0	0
Exposure after consideration of SNDS data for patients without confirmed SB5 discontinuation and with available SNDS data								
Less than 12 months	3 (3.9%)	0 (0.0%)	1 (4.0%)	4 (3.4%)	6 (5.9%)	1 (7.1%)	7 (6.0%)	11 (4.7%)
More than 12 months	74 (96.1%)	16 (100%)	24 (96.0%)	114 (96.6%)	96 (94.1%)	13 (92.9%)	109 (94.0%)	223 (95.3%)
Missing data	0	0	0	0	0	0	0	0

Supplementary Table S2 – B: impact of SNDS data on persistence

	< 12 months of exposure with SNDS data (N=441)	> 12 months of exposure with SNDS data (N=470)	Total (N=911)
Exposure before consideration of SNDS data			
< 12 months of exposure without SNDS data	11 (100%)	57 (25.6%)	68 (29.1%)
> 12 months of exposure without SNDS data	0 (0.0%)	166 (74.4%)	166 (70.9%)
Missing data	0	0	0